cancer-biology

がんバイオロジー MOC

がん種非依存の横断的バイオロジー (hallmarks of cancer、代謝、幹細胞、転移一般、骨転移) を統合する。肺がん固有の機序は lung-cancer-biology で扱う。

ドメイン定義

含む: hallmarks of cancer (2026 拡張版: 9 機能的特性 + 5 促進的表現型特性 + 腫瘍微小環境 (tumor microenvironment, TME) 構成細胞 + 全身性相互作用)、metabolic reprogramming (Warburg, glutamine / ミトコンドリアグルタミン輸送 (mitochondrial glutamine import, MGI), 脂質代謝)、cancer stem cell / 表現型可塑性、EMT (上皮間葉転換, epithelial-mesenchymal transition) / MET (間葉上皮転換, mesenchymal-epithelial transition)、骨転移 (一般)、脈管侵襲、ferroptosis / pyroptosis 等の regulated cell death、細胞外マトリックス (extracellular matrix, ECM) remodeling / fibrotic niche、細胞老化 (senescence)、cancer neuroscience、cancer ecosystem としての多階層動態、cancer-immune crosstalk の基礎機序。

含まない: 肺がん固有の driver / 病態 (→ lung-cancer-biology)、特定の臓器転移 (脳: cancer-brain-metastasis、骨: 本 MOC 扱い)、myeloid 細胞・好中球 (→ cancer-neutrophils)、細胞外小胞 (extracellular vesicle, EV) (→ cancer-extracellular-vesicles)。

Basic-Others 内の論文は内容で振り分け: 肺がん特異的 → lung-cancer-biology、それ以外の汎がん種研究 → 本 MOC。

現状の合意 (State of the Field)

がんバイオロジーは Hanahan & Weinberg の 2000/2011 hallmarks フレームから 2026 の拡張版へと再構成され、現在では「9 つの獲得された機能的特性 + 5 つの促進的表現型特性 + 腫瘍微小環境を構成する異種細胞 + 全身性相互作用」という 4 次元フレームとして体系化されている (Hanahan et al. Cell 2026)。表現型可塑性、非変異原性エピゲノム再プログラミング、多倍体化、神経支配、微生物叢、細胞老化が促進的特性の候補として組み込まれ、単一 hallmark 標的薬 (免疫チェックポイント阻害薬 (immune checkpoint inhibitor, ICI)、抗血管新生薬、KRAS G12C 阻害薬) の内在性/適応性抵抗性を踏まえたメカニズム基盤の共同標的化 (例: 抗 VEGFA 抗体ベバシズマブと PD-1 抗体ペムブロリズマブの併用は進行腎細胞癌で無増悪生存期間 (progression-free survival, PFS) を約 12 ヶ月 vs 7 ヶ月、ハザード比 (hazard ratio, HR) 0.65 へ延長し既に臨床承認) が次世代治療戦略の軸となった (Hanahan et al. Cell 2026)。細胞老化は安定増殖停止・クロマチンリモデリング・細胞死抵抗性・老化随伴分泌形質 (senescence-associated secretory phenotype, SASP)・微小環境センシング変化・代謝再編という 6 特徴で整理され、単一マーカーに依らない連続体概念 senotype のもとで腫瘍抑制と腫瘍促進の二面性をもつ paradox として再評価され、senolytics (D+Q, navitoclax, fisetin) や間質を再構築する uPAR-CAR-T が治療応用に向かっている (Hinterleitner et al. Cell 2026)。神経-腫瘍 crosstalk (cancer neuroscience) も発生・増殖・転移・治療抵抗性を貫く軸として確立された (Winkler et al. Cell 2026)。

代謝リプログラミングは Warburg effect 単独説から脱却し、Warburg 効果自体が増殖に必要な NAD+ (nicotinamide adenine dinucleotide) 再生の帰結であって代謝原理は正常細胞にも普遍的に適用される統合機能として再定義された (Finley et al. Cell 2023)。近年は glutaminolysis に依らないミトコンドリアへの直接グルタミン輸送 (MGI) が SLC1A5 splice variant を介して、全ミトコンドリア aa-tRNA 中で最も律速な Gln-mt-tRNA^Gln 生合成 → ミトコンドリア翻訳 → 電子伝達系 (electron transport chain, ETC) 完全性を維持する独立軸として同定され、その阻害は外因性グルタミン酸で救済できない ETC 崩壊と in vivo 腫瘍抑制 (V9302 投与で腫瘍体積 約70% 減) を引き起こした (Zhu et al. MolCell 2026)。これはグルタミナーゼ (glutaminase, GLS) 阻害薬 CB839 の限定的な臨床効果に対する治療標的の刷新を示唆する。代謝可塑性は免疫療法とも接続し、16 時間絶食レジメンが腫瘍内イソロイシン蓄積を介して CD8+ T 細胞の抗腫瘍能を増強することがマウス・ヒトで示された (Chen et al. CellMetab 2026)。

細胞可塑性は EMT を中心に再定式化され、EMT は二値的スイッチではなく可逆的・連続的なハイブリッド状態の連続体として腫瘍開始・浸潤・免疫回避・治療抵抗性・転移ニッチ統合を駆動する central driver と位置づけられた。乳癌では SNAIL1 → TWIST → PRRX1 の順次活性化による胚様浸潤性 EMT (PRRX1+ 細胞が転移性集団) と、SNAIL1 駆動で抗腫瘍性 MHC-II+ マクロファージを伴う炎症性 EMT という機能的に拮抗する 2 軌跡が同定され、PRRX1 抑制で前者を後者へ転換でき、また ZEB1 が多価不飽和:一価不飽和脂肪酸 (polyunsaturated:monounsaturated fatty acid, PUFA:MUFA) 比上昇を介して SNAIL1/TWIST には無い特異的フェロトーシス脆弱性 (GPX4 阻害 IC50 約 50 nM) を付与することが示された (Jimenez-Castano et al. NatCancer 2026)。TGFβ 駆動の atypical EMT はゲルソリンを介して細胞硬度を低下させ免疫メカノサーベイランスを回避し、肺腺癌の休眠転移を成立させる (Wang et al. NatCancer 2026)。同様の非遺伝的可塑性は早期がんでも普遍的で、T1 大腸がんの浸潤前縁に転移能関連のがん胎児性 (oncofetal) 細胞状態が出現し、隣接する栄養芽様がん関連線維芽細胞 (cancer-associated fibroblast, CAF) が TGFβ + プロスタグランジンでこれを誘導する (Buissant et al. Nature 2026)。

微小環境はがん化以前から腫瘍化を方向づける。早期 fibrotic niche が Kras 変異 II 型肺胞上皮 (alveolar type II, AT2) 細胞の再生様一過性前駆細胞 (damage-associated transient progenitor, DATP) 状態 → AREG 分泌 → 隣接線維芽細胞の EGFR 活性化を介して tumour-permissive な間質を構築し、間質線維化 → ECM stiffening → 免疫排除 → 治療抵抗性という cascade の起点を腫瘍化以前に同定した (Cardoso et al. Nature 2026)。CAF は「空間ニッチ × 転写状態 × 細胞起源」の三次元で再整理され、腫瘍隣接・血管周囲・三次リンパ構造 (tertiary lymphoid structure, TLS)・神経周囲の 4 空間ニッチで筋線維芽細胞様 (myCAF)・炎症性 (iCAF)・抗原提示性 (apCAF) として高度に不均一かつ可塑的であり、myCAF/iCAF 間は TGFβ と IL-1 のシグナル強度バランスで動的に相互変換する。TGFβ 依存的に形成される LRRC15+ myCAF は T 細胞の物理的排除を主導して免疫チェックポイント阻害 (immune checkpoint blockade, ICB) 抵抗性の共通軸となり、SASP を呈する senescent CAF は NK (natural killer) 細胞傷害を抑制する (Pramod et al. NatCancer 2026)。骨転移では RANK-RANKL-osteoclast vicious cycle を core としつつ、Sortase A ベースのニッチ標識技術 SAMENT によって ERα 陽性マクロファージが T 細胞を排除する immune-excluded niche が可視化され、がん細胞由来脂肪酸 → PPARγ → Esr1 誘導という分子回路が同定された (骨髄系特異的 Esr1 欠失で T 細胞浸潤が回復し骨転移を 5-10 倍抑制、原発臓器非依存でヒト男性検体でも確認) (Xu et al. Cell 2026)。

細胞死モダリティはアポトーシス回避という古典 hallmark を超えて、ネクロトーシス・パイロトーシス・フェロトーシス・クプロトーシス・ジスルフィドプトーシス・NETosis 等の regulated cell death を相互接続したネットワークとして再概念化する段階に入った。BH3 ミメティクス venetoclax (慢性リンパ性白血病 (chronic lymphocytic leukemia, CLL)/急性骨髄性白血病 (acute myeloid leukemia, AML) で承認、固形癌では BCL-XL/MCL-1 デュアル阻害が必要) を細胞死標的療法のプロトタイプとし、免疫原性細胞死 (ICD) は adjuvanticity・antigenicity・炎症性 context の 3 要素で規定され、ネクロトーシス/パイロトーシスが最も免疫原性が高くフェロトーシスは低い、という modality 間の序列が整理された (Conrad et al. Cell 2026)。フェロトーシスでは腫瘍の酸性微小環境で HIF-1α と TGFβ が収束して syndecan-1 のグリカンをヘパラン硫酸 (heparan sulfate, HS) からコンドロイチン硫酸 (chondroitin sulfate, CS) へ転換してグライコカリックスをリモデリングし、脂質スカベンジングを抑えてフェロトーシス抵抗性を付与する一方、CS 合成と DGAT1 の二重阻害が壊滅的な脂質過酸化で膠芽腫 (glioblastoma, GBM) 異種移植モデルの生存を延長した (n=10 mice, p=0.0028) (Bang-Rudenstam et al. NatCellBiol 2026)。ストレス顆粒がフェリチンを隔離して不安定鉄プールを制限する抑制機構も同定され、G3BP1-FTL 軸を標的とする低分子化合物 CWJ-C3 が GBM 幹細胞の放射線・テモゾロミド (temozolomide, TMZ) 感受性を回復させた (HR=0.18) (Ge et al. NatCellBiol 2026)。臨床橋渡しは薬理学的限界・腫瘍内不均一性・微小環境制約を主課題とする translational roadmap に整理されている (Kang et al. NatRevClinOncol 2026)。

最上位の組織化軸として、がんは分子・細胞・組織・臓器間・全身生理・時間軸を横断する multi-scale ecosystem として再概念化された。宿主のマクロ環境 (性差・加齢・微生物叢・概日リズム・食事・運動・PM2.5 など環境曝露) が免疫トーンを連続的に較正し、空間配置こそが治療応答を規定する (mregDC + CXCL13+ CD4 + 前駆 CD8 の樹状細胞 (dendritic cell, DC) triad/tetrad が anti-PD-1 応答の最小機能単位、運動由来の代謝産物が CD8+ T 細胞ミトコンドリアを賦活、BCG/β-glucan の trained immunity が持続的監視を付与) ことが示され、治療概念は「悪性細胞の単独除去」から「エコシステム全体の修復」へ転換した (Quail et al. Cell 2026)。EV・サイトカイン・神経内分泌系を統合した遠隔臓器の systemic pre-conditioning がこれを補強する (Rabas et al. NatRevCancer 2024)。進化生物学の視点では、正常組織にドライバー変異クローンが遍在し非変異原性発癌物質が選択圧として働くため、発癌は「変異 × 選択」のダーウィン的相互作用として再構成された (Lopez-Bigas et al. Nature 2026)。患者年齢分布を用いて選択と発癌原因を統計的に分離する枠組みも提示され (Cheek et al. NatGenet 2026)、PEACE 研究は白金 6 コースが血液で約 27 加齢年相当の変異を誘発し免疫療法が TP53 / PPM1D の非変異原性選択圧として働くことを実証した (Pich et al. Nature 2026)。ゲノム不安定性自体も標的化対象として体系化され (Yap et al. Cell 2026)、セントロメアを欠く染色体外 DNA (ecDNA) が CpG リッチな活性プロモーター由来の retention element を介して有糸分裂ブックマーク領域へ繋留され細胞分裂を超えて維持される機構が同定され、その element の標的 CpG メチル化が ecDNA 喪失を誘導しうることが示された (Sankar et al. Nature 2026)。

主要エンティティ

関連遺伝子 (Tumor suppressor / pleiotropic regulators)

• TP53 — pan-cancer 最頻 mutation (NSCLC 65–80%), p53 LOF / GOF
• MYC — bHLH master regulator, c-MYC / MYCN / MYCL family, transcriptional addiction
• RB1 — G1/S checkpoint, SCLC dual loss baseline, lineage plasticity facilitator

関連薬剤クラス (cell death / metabolism / DDR)

• PARP-inhibitor — DDR synthetic lethality (BRCA / HRD / SLFN11+ subset)
• Platinum-chemotherapy — DNA cross-link、cell death modality classical paradigm

主要概念

• NETosis-cancer-metastasis — NET-CCDC25 軸、休眠覚醒、CTC trapping
• Pre-metastatic-niche — EV organotropism、BMDC 動員、ECM remodeling
• Lineage-plasticity — HPCS hub、neuroendocrine transformation
• EMT — 上皮-間葉転換、partial/hybrid EMT、転移・治療抵抗性 central mechanism
• Cancer-dormancy — DTC 休眠、awakening triggers、MRD biology

(Phase D 拡張候補: hallmarks 各論 / metabolic reprogramming / cancer stem cell / bone metastasis vicious cycle / ferroptosis / immune-excluded niche)

Open Questions

• Hallmarks の次元拡張：cancer neuroscience、cancer ecosystem dynamics、機械力学的特性、多倍体化は独立 hallmark として確立されるか、また senescence の有益/有害 (senotype 別) を切り分けて選択的にセノリティクスを適用する分子基準をどう確立するか
• 代謝標的療法の臨床橋渡し：MGI (SLC1A5 splice variant) や glutamine/cystine/lipid 軸の患者層別化バイオマーカーと耐性回避戦略、ミトコンドリア局在を選択的に狙う特異的 MGI 阻害薬の開発、絶食など代謝介入と免疫療法の併用最適化
• 細胞可塑性の薬理学的制御：ハイブリッド EMT 状態を pharmacologically lock する手法、PRRX1 抑制による浸潤性 → 炎症性 EMT 軌跡シフトの汎用性、ZEB1 特異的フェロトーシス脆弱性の臨床利用、oncofetal / lineage plasticity の可逆性
• 微小環境の先制介入：腫瘍化以前の fibrotic niche や骨髄 immune-excluded niche を画像化・モニタリングする liquid / imaging biomarker、正常線維芽細胞を傷つけず腫瘍促進的 CAF サブタイプ (LRRC15+ myCAF 等) のみを選択標的化・リプログラムする手法
• Regulated cell death の治療応用：ferroptosis / pyroptosis 誘導と ICD の臨床最適化、フェロトーシスの低免疫原性の克服、酸性グライコカリックス (HS→CS スイッチ)・ストレス顆粒・薬剤耐性パーシスターを突く順序と毒性管理
• エコシステム視点の臨床実装：DC triad/tetrad など空間ネットワークのルーチン計測、概日リズム・性周期に基づく chronotherapy、運動・食事・微生物叢による systemic conditioning を真の治療軸とする前向き試験
• 治療誘発進化の管理：化学療法・免疫療法が正常組織と腫瘍に及ぼす変異誘発性/非変異原性選択圧 (TP53/PPM1D 等) と、CpG メチル化を介した ecDNA retention element 維持機構を先制的にどう抑えるか

重要論文 Top 10

1. ★★★★★ Hanahan et al. Cell 2026 — Hallmarks 2026 拡張版、cancer biology 指導枠組み
2. ★★★★★ Finley et al. Cell 2023 — 代謝リプログラミング現代的再定義
3. ★★★★ Jimenez-Castano et al. NatCancer 2026 — EMT を可塑性の central driver として再定式化
4. ★★★★ Xu et al. Cell 2026 — 骨転移 immune-excluded niche の空間マッピング
5. ★★★★ Bang-Rudenstam et al. NatCellBiol 2026 — acidosis-glycocalyx-ferroptosis 軸の統合
6. ★★★★ Sharma et al. Cell 2023 — Immune checkpoint therapy 現代 paradigm 統合
7. ★★★★ Galassi et al. CancerCell 2024 — Immune evasion hallmarks 統合フレーム
8. ★★★★ Marine et al. NatRevCancer 2020 — Non-genetic resistance paradigm (dormancy/lineage shift/EMT を統合)
9. ★★★★ Quail et al. Cell 2026 — Cancer ecosystems multi-scale dynamics の統合
10. ★★★★ Conrad et al. Cell 2026 — Regulated cell death (ferroptosis/pyroptosis/necroptosis) の cancer 文脈

最新追加論文 Top 10

• Jong et al. JImmunotherCancer 2026 — Basic-Others
• Wang et al. Carcinogenesis 2026 — Basic-Others
• Xu et al. CancerCell 2026 — Basic-Others
• Goto et al. Nature 2024 — Basic-Others
• Li et al. CancerImmunolRes 2026 — Basic-Others
• Shukla et al. NatBiotechnol 2015 — Basic-Others
• Weickhardt et al. JThoracOncol 2012 — Basic-Others
• Nik-Zainal et al. Cell 2012 — Basic-Others
• Repetto et al. ClinCancerRes 2026 — Basic-Others
• De et al. NatMed 2026 — Basic-Others

全論文リスト (カテゴリ別、自動生成)

Basic-Others

• Gan et al. AdvSci 2026 — Single-cell reveal GALNT7-dependent ferroptosis suppression as a mechanism of immunotherapy resistance in non-small
• Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer
• ODwyer et al. BMJOncol 2026 — Treatment of oligometastatic lung cancers new data, new drivers, new approaches
• Enssle et al. CancerCell 2026 — Pathogenesis of diffuse large B cell lymphoma proteogenotypes
• Liang et al. CancerCell 2026 — Spatial biomarker discovery via interpretable semantic learning in histopathology
• Richter et al. CancerCell 2026 — A closed tumor-immune-brain circuit in cancer cachexia
• Tang et al. CancerCell 2026 — Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer
• Xu et al. CancerCell 2026 — Received 24 february 2026
• Zhang et al. CancerCell 2026 — Cancer cachexia a tumor-driven disorder of whole-body homeostasis
• Marinello et al. CancerDiscov 2026 — Approaches in non-small cell lung cancer 2
• Winslow et al. CancerDiscov 2026 — A roadmap to transform lung cancer outcomes priorities in biology, therapeutic innovation, early detection, prevention
• Yiu et al. CancerDiscov 2026 — Same-slide spatial multiomics integration
• Li et al. CancerImmunolRes 2026 — Peripheral th17 immune signature associates with excellent response to anti-PD1anti-PD-L1 therapy across solid tumors
• Muneer et al. CancerLett 2026 — Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC A multi-center
• Zhu et al. CancerMed 2026 — Harnessing gut microbiota to enhance immunotherapy in NSCLC from mechanisms to translational applications
• Clarke et al. CancerRes 2026 — Virtual tumors enable prediction of personalized therapeutic combinations for non-small cell lung cancer
• Jiang et al. Cancers 2026 — Selective inhibition of KRASG13C reveals an increased dependence on wild-type RAS
• Wang et al. Carcinogenesis 2026 — Camrelizumab, apatinib and radiotherapy in locally advanced, unresectable
• Aggarwal et al. Cell 2026 — Engineered commensals for metabolic modulation of the gut-liver-brain axis
• Conard et al. Cell 2026 — Tackling the complexity of cancer with generative models
• Conrad et al. Cell 2026 — Cell death in cancer
• Dohlman et al. Cell 2026 — Biodiversity and biogeography of the multi-kingdom cancer microbiome
• Gao et al. Cell 2026 — Nanoparticles hijack calvarial immune cells for CNS drug delivery and stroke therapy
• Hanahan et al. Cell 2026 — Hallmarks of cancer-then and now, and beyond
• Hinterleitner et al. Cell 2026 — Senescence in cancer hallmarks, paradoxes, and therapeutic promise
• Ho et al. Cell 2026 — Transposable element DNA and RNA drivers of gene expression, evolution, and disease
• Li et al. Cell 2026 — Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology
• Li et al. Cell 2026 — Multimodal clocks of human aging
• Quail et al. Cell 2026 — Cancer ecosystems a dynamic interplay across scales
• Song et al. Cell 2026 — Hijacking ERAD for targeted degradation of transmembrane proteins
• Tzouanas et al. Cell 2026 — Hepatic adaptation to chronic metabolic stress primes tumorigenesis
• Ueki et al. Cell 2026 — A CRISPR knockout mouse library for functional genomics in influenza research
• Winkler et al. Cell 2026 — Cancer neuroscience the past, the present, and the road ahead
• Xing et al. Cell 2026 — Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional
• deLaunoit et al. Cell 2026 — The spatiotemporal dynamics of postnatal vascularization in the mouse brain
• Gao et al. CellMetab 2026 — The s100a8a9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice
• Jia et al. CellMetab 2026 — Plasma proteomic signature of frailty in 50,506 adults
• Liang et al. CellMetab 2026 — Large-scale metaproteomics of human gut microbiota reveals microbial functions in metabolic diseases and aging
• Tiwari et al. CellRep 2026 — An orally active dual CBPp300 degrader targets core dependencies of multiple myeloma
• Chae et al. ClinCancerRes 2026 — Mitochondrial imaging detects early cardiac changes following cancer immunotherapy
• Repetto et al. ClinCancerRes 2026 — The genomic landscape of MYC, MYCL, and MYCN amplified solid tumors
• Zhang et al. JAMA 2026 — An AI-based OCT system to detect diabetic macular edema
• Strohbehn et al. JCOOncolPract 2026 — Maintenance PemetrexedPembrolizumab versus pembrolizumab in non-small cell lung cancer A propensity score-weighted
• Morigny et al. JClinInvest 2026 — Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model
• Rochelle et al. JClinInvest 2026 — Leveraging factors that control alveolar epithelial cell fate enables large-scale expansion for lung tissue engineering
• Ruggero et al. JClinInvest 2026 — Rewriting the cancer proteome targeting selective translation as a
• Oberstein et al. JClinOncol 2026 — Amivantamab monotherapy in chemorefractory RASBRAF wild-type metastatic colorectal cancer results from OrigAMI-1, an
• Abascal et al. JImmunotherCancer 2026 — FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine
• Chen et al. JImmunotherCancer 2026 — Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of
• Jong et al. JImmunotherCancer 2026 — Lenalidomide boosts CD1d-vdelta2 bispecific antibody-engaged Vgamma9Vdelta2-T cell effector functions via CD28, notch
• Zhang et al. JImmunotherCancer 2026 — HDAC inhibitors reverse YAP-driven immune resistance in NSCLC mechanistic and translational evidence
• Zhang et al. MolCell 2026 — PKCalpha-mediated nuclear translocation of cGAS stabilizes beta-catenin and drives metastasis
• Zhu et al. MolCell 2026 — Mitochondrial glutamine import sustains electron transport chain integrity independently of glutaminolysis in cancer
• Centre et al. NEnglJMed 2026 — Sodium bicarbonate for critically ill adults with metabolic acidosis and shock
• Cohn et al. NEnglJMed 2026 — Lonvoguran ziclumeran-in vivo CRISPR gene editing in hereditary angioedema
• Haber et al. NEnglJMed 2026 — Altering the diet to rewire cancer
• OReilly et al. NEnglJMed 2026 — Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
• Lu et al. NatAging 2026 — Proteomic signatures of the APOE epsilon4 and APOE epsilon2 genetic variants and alzheimer’s disease
• Zhou et al. NatBiotechnol 2026 — Digital twins of ex vivo human lungs enable accurate and personalized evaluation of therapeutic efficacy
• Frangieh et al. NatCancer 2026 — Single-cell and spatial profiling in cancer biology and clinical oncology
• Gfeller et al. NatCancer 2026 — Advances in predicting t cell epitope recognition for cancer immunotherapy
• Jimenez-Castano et al. NatCancer 2026 — Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity
• Ge et al. NatCellBiol 2026 — Stress granules restrain ferroptosis by sequestering ferritin
• Krey et al. NatCommun 2026 — The ISG atlas a loss-of-function analysis characterizes antiviral properties of interferon stimulated genes
• Radke et al. NatCommun 2026 — RBM20 isoform regulation by independent transcription start sites adapts alternative splicing in development and disease
• Cheruiyot et al. NatGenet 2026 — Inflammatory cytokines induce new cancer dependencies
• Sarni et al. NatGenet 2026 — A progeria syndrome links DNA hypermethylation to age-related pathology
• De et al. NatMed 2026 — Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER
• Ding et al. NatMed 2026 — Plasma proteomic signatures of cellular aging predict human disease
• Gentner et al. NatMed 2026 — Tumor-targeted interferon-alpha gene therapy for glioblastoma a phase 1 trial
• Ke et al. NatMed 2026 — AI-induced never-skilling in medical education
• Peng et al. NatMed 2026 — Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma a phase 2 trial
• Jiang et al. NatNanotechnol 2026 — Efficient prime editing in vivo and in vitro using lipid nanoparticles
• Sanchez-Molina et al. NatNeurosci 2026 — Spatial proteomic analysis in human alzheimer’s disease brains enables identification of microenvironment-dependent
• Zhu et al. NatProtoc 2026 — Differential protein expression analysis of quantitative mass spectrometry data using deqms
• Rowles et al. NatRevCancer 2026 — Decoding cancer across scales with metabolomics
• Saviano et al. NatRevCancer 2026 — Claudin proteins as emerging therapeutic targets for solid tumours
• Pike et al. NatRevChem 2026 — Lessons learned in linking PROTACs from discovery to the clinic
• Chen et al. NatRevClinOncol 2026 — Engineering platelets as cancer therapeutics
• Kang et al. NatRevClinOncol 2026 — Translating ferroptosis into oncology challenges, opportunities and future directions
• Guilbaud et al. NatRevDrugDiscov 2026 — Autophagy modulation in cancer
• Monroe et al. NatRevDrugDiscov 2026 — Therapeutic targeting of neuroimmune mechanisms in neurodegeneration
• Lee et al. NatRevImmunol 2026 — Glial cells in chronic inflammation diversity, dysfunction and therapeutic targeting
• Turner et al. NatRevImmunol 2026 — RNA-binding proteins and ribonucleoproteins as determinants of immunity
• Ehlers et al. NatRevNeurosci 2026 — Wired for immunity neuroimmune control of the lung by sensory neurons
• Brixi et al. Nature 2026 — Genome modelling and design across all domains of life with evo 2
• Davis et al. Nature 2026 — 25 years of chemistry that simply clicks
• Gerhardt et al. Nature 2026 — Mutation-dependent responses to sleep and exercise in clonal haematopoiesis
• Li et al. Nature 2026 — Spermine is an endogenous iron chelator that inhibits ferroptosis
• Lu et al. Nature 2026 — Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
• Menendez-Montes et al. Nature 2026 — Mitochondria directly interact with the nuclear pore complex
• Scholz et al. Nature 2026 — RNA-triggered cell killing with crispr-cas12a2
• Yan et al. Nature 2026 — Ecotypes of triple-negative breast cancer in response to chemotherapy
• Yue et al. Nature 2026 — Spatial distribution of the proteome in the human body and in cancers
• Zeng et al. Nature 2026 — Human haematopoietic stem cells remember inflammatory stress
• Zhang et al. Nature 2026 — The mutational landscape of STING-induced immunity
• Lee et al. Neuron 2026 — Immune-brain plasticity underpins stress and affective behaviors
• Liu et al. OncolRev 2026 — Progress in the application of 68ga-pentixafor petct in lung cancer a review
• Dymun et al. SciTranslMed 2026 — Clinicogenomic analysis of
• Western et al. SciTranslMed 2026 — Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease
• Kim et al. Science 2026 — Complex interplay of neuronal and hormonal gut-brain responses to essential amino acid deficit
• Lin et al. Science 2026 — Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency
• Pearce et al. Science 2026 — Transcriptformer a generative cell atlas across 1.5 billion years of evolution
• Davalos et al. TrendsCancer 2026 — How DNA methylation predicts response to cancer therapies
• Janiak et al. TrendsCancer 2026 — Platelets the next-generation ovarian cancer biomarker
• Conrad et al. Blood 2025 — Decoding functional hematopoietic progenitor cells in the adult human lung
• Maltseva et al. MolOncol 2025 — Interplay of integrins and selectins in metastasis
• DeMichele et al. NatMed 2025 — Targeting dormant tumor cells to prevent recurrent breast cancer a randomized phase 2 trial
• Laisne et al. NatRevCancer 2025 — Epigenomic heterogeneity as a source of tumour evolution
• Leunig et al. NatRevImmunol 2025 — Connection and communication between the nervous and immune systems
• Hoover et al. Nature 2025 — Nerve-to-cancer transfer of mitochondria during cancer metastasis
• Li et al. Nature 2025 — SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer
• Li et al. ProcNatlAcadSciUSA 2025 — Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected
• Liaki et al. ProcNatlAcadSciUSA 2025 — A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
• Bojmar et al. NatMed 2024 — Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer
• Goto et al. Nature 2024 — SOX17 enables immune evasion of early colorectal adenomas and cancers
• Chen et al. iScience 2024 — Translating CD47-targeted therapy in gastrointestinal cancers insights from preclinical to clinical studies
• Falzone et al. Cell 2023 — Cancer chemotherapy
• Finley et al. Cell 2023 — What is cancer metabolism
• Horns et al. Cell 2023 — Engineering RNA export for measurement and manipulation of living cells
• Shiraishi et al. Cell 2023 — Biophysical forces mediated by respiration maintain lung alveolar epithelial cell fate
• Wang et al. CellDeathDiscov 2023 — Role of ADAM and ADAMTS proteases in pathological tissue remodeling
• Tanaka et al. FEBSOpenBio 2023 — A mouse model of lung cancer induced via intranasal injection for anticancer drug screening and evaluation of pathology
• Sharp et al. FrontImmunol 2023 — Experimental procedures for flow cytometry of wild-type mouse brain a systematic review
• Aoki et al. InVivo 2023 — Precise and facile endotracheal lung-tumor-implantation mouse model visualized by GFP expression
• Atkins et al. JClinOncol 2023 — Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced
• Hadoux et al. NEnglJMed 2023 — Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer
• Goswami et al. NatCancer 2023 — Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade
• Sikkema et al. NatMed 2023 — An integrated cell atlas of the lung in health and disease
• Malfertheiner et al. NatRevDisPrimers 2023 — Helicobacter pylori infection
• Zhang et al. ProcNatlAcadSciUSA 2023 — Integrin alpha5beta1 contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent
• Pennitz et al. STARProtoc 2023 — Protocol to dissociate healthy and infected murine-and hamster-derived lung tissue for single-cell transcriptome anal…
• Chen et al. BiomedPharmacother 2022 — Integrin-mediated cancer progression as a specific target in clinical therapy
• Heazlewood et al. Blood 2022 — The RNA-binding protein SRSF3 has an essential role in megakaryocyte maturation and platelet production
• Wen et al. Blood 2022 — Molecular mechanisms of leukocyte beta2 integrin activation
• Newell et al. CancerCell 2022 — Multiomic profiling of checkpoint inhibitor-treated melanoma identifying predictors of response and resistance, and
• Garciaz et al. CancerDiscov 2022 — Pharmacologic reduction of mitochondrial iron triggers a noncanonical BAXBAK-dependent cell death
• Mirzalieva et al. Cells 2022 — ISG15 and ISGylation in human diseases
• Kang et al. ExpMolMed 2022 — The diverse repertoire of ISG15 more intricate than initially thought
• Rugo et al. JClinOncol 2022 — Sacituzumab govitecan in hormone receptor-PositiveHuman epidermal growth factor receptor 2-negative metastatic breast
• Christian et al. MethodMolBiol 2022 — Cancer cell biology
• Ferguson et al. NatCommun 2022 — The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug
• Mirhadi et al. NatCommun 2022 — Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes
• Song et al. NatCommun 2022 — Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues
• LeSavage et al. NatMater 2022 — Next-generation cancer organoids
• Nurk et al. Science 2022 — The complete sequence of a human genome
• Hollox et al. TrendsGenet 2022 — Genome structural variation in human evolution
• Zhu et al. CancerCell 2021 — Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription
• Hao et al. Cell 2021 — Integrated analysis of multimodal single-cell data
• Schreiber et al. Cell 2021 — The rise of molecular glues
• Flamini et al. CellDeathDis 2021 — Glucocorticoid-induced leucine zipper regulates liver fibrosis by suppressing CCL2-mediated leukocyte recruitment
• Yang et al. CellRep 2021 — Dimensionality reduction by UMAP reinforces sample heterogeneity analysis in bulk transcriptomic data
• Kay et al. CellsDev 2021 — Macropinocytosis biology and mechanisms
• Wu et al. Innovation(Camb) 2021 — clusterProfiler 4.0 A universal enrichment tool for interpreting omics data
• Martinez-Arroyo et al. IntJMolSci 2021 — Small rab GTPases in intracellular vesicle trafficking the case of Rab3ARaphillin-3a complex in the kidney
• Borchers et al. JCellBiol 2021 — Who’s in control principles of rab GTPase activation in endolysosomal membrane trafficking and beyond
• Kanemitsu et al. JClinOncol 2021 — Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic,
• Winer et al. LancetOncol 2021 — Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119) a
• Alvero et al. MethodMolBiol 2021 — Detection of cell death mechanisms
• Cuklina et al. MolSystBiol 2021 — Diagnostics and correction of batch effects in large-scale proteomic studies a tutorial
• Vancura et al. NARCancer 2021 — Cancer LncRNA census 2 (CLC2) an enhanced resource reveals clinical features of cancer lncRNAs
• Burley et al. NEnglJMed 2021 — Predicting proteome-scale protein structure with artificial intelligence
• Choueiri et al. NEnglJMed 2021 — Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
• Motzer et al. NEnglJMed 2021 — Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
• Tanaka et al. NatCancer 2021 — Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic
• Choi et al. NatCellBiol 2021 — Release of notch activity coordinated by IL-1beta signalling confers differentiation plasticity of airway progenitors
• Rozeman et al. NatMed 2021 — Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
• Rennick et al. NatNanotechnol 2021 — Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics
• Rottenberg et al. NatRevCancer 2021 — The rediscovery of platinum-based cancer therapy
• Koh et al. ProcNatlAcadSciUSA 2021 — A short ORF-encoded transcriptional regulator
• Rosin et al. STARProtoc 2021 — Live-cell imaging of microglial interactions with radial glia in transgenic embryonic mouse brains using slice culture
• Altae-Tran et al. Science 2021 — The widespread IS200IS605 transposon family encodes diverse programmable RNA-guided endonucleases
• Ishiwata et al. TranslLungCancerRes 2021 — A preclinical research platform to evaluate photosensitizers for transbronchial localization and phototherapy of lung
• Graw et al. ACSOmega 2020 — proteiNorm-A user-friendly tool for normalization and analysis of TMT and label-free protein quantification
• Wilkinson et al. AnnuRevBiochem 2020 — RNA splicing by the spliceosome
• Sinha et al. Biochemist 2020 — A beginner’s guide to mass spectrometry-based proteomics
• Zhao et al. CancerCell 2020 — Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines
• Nolan et al. CancerCellInt 2020 — Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models
• Dijkstra et al. CellRep 2020 — Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine
• Choi et al. CellStemCell 2020 — Inflammatory signals induce AT2 cell-derived damage-associated transient progenitors that mediate alveolar regeneration
• Yao et al. CellStemCell 2020 — Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer
• Miklavc et al. Cells 2020 — Actin and myosin in non-neuronal exocytosis
• Schioppa et al. FrontCellDevBiol 2020 — Molecular basis for CCRL2 regulation of leukocyte migration
• Lucotti et al. FrontOncol 2020 — Platelets and metastasis New implications of an old interplay
• Calvo et al. IBRORep 2020 — Dissociation of neonatal and adult mice brain for simultaneous analysis of microglia, astrocytes and infiltrating
• Kojima et al. JClinOncol 2020 — Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
• Ernst et al. JMedChem 2020 — Design of development candidate eFT226, a first in class inhibitor of eukaryotic initiation factor 4a RNA helicase
• Elsallab et al. LancetOncol 2020 — CAR T-cell product performance in haematological malignancies before and after marketing authorisation
• Powles et al. LancetOncol 2020 — Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma
• Aguilan et al. MolOmics 2020 — Guide for protein fold change and p-value calculation for non-experts in proteomics
• Alzahofi et al. NatCommun 2020 — Rab27a co-ordinates actin-dependent transport by controlling organelle-associated motors and track assembly proteins
• Algazi et al. NatMed 2020 — Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma a randomized phase 2 trial
• Deng et al. NatMed 2020 — Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large
• Slyper et al. NatMed 2020 — A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
• Driehuis et al. NatProtoc 2020 — Establishment of patient-derived cancer organoids for drug-screening applications
• Rohatgi et al. NatRevClinOncol 2020 — Cancer vaccine induces potent T cell responses-but is it enough
• Konigs et al. NatStructMolBiol 2020 — SRSF7 maintains its homeostasis through the expression of split-ORFs and nuclear body assembly
• Gilan et al. Science 2020 — Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
• Stuart et al. Cell 2019 — Comprehensive integration of single-cell data
• Wagner et al. Cell 2019 — A single-cell atlas of the tumor and immune ecosystem of human breast cancer
• Li et al. ClinCancerRes 2019 — The immune subtypes and landscape of squamous cell carcinoma
• Yan et al. ColdSpringHarbPerspectBiol 2019 — Molecular mechanisms of pre-mRNA splicing through structural biology of the spliceosome
• Hafemeister et al. GenomeBiol 2019 — Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression
• Xue et al. NatCommun 2019 — CDK46 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
• Korsunsky et al. NatMethods 2019 — Fast, sensitive and accurate integration of single-cell data with harmony
• Stuart et al. NatRevGenet 2019 — Integrative single-cell analysis
• Chan et al. Nature 2019 — Molecular recording of mammalian embryogenesis
• Tikhonova et al. Nature 2019 — The bone marrow microenvironment at single-cell resolution
• Lee et al. Cell 2018 — Tumor evolution and drug response in patient-derived organoid models of bladder cancer
• Stillman et al. Cell 2018 — Histone modifications insights into their influence on gene expression
• Atkins et al. ClinCancerRes 2018 — Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma
• Maloney et al. ClinOrthopRelatRes 2018 — Intratibial injection causes direct pulmonary seeding of osteosarcoma cells and is not a spontaneous model of
• Wolf et al. GenomeBiol 2018 — SCANPY large-scale single-cell gene expression data analysis
• DiNardo et al. NEnglJMed 2018 — Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML
• Mejean et al. NEnglJMed 2018 — Sunitinib alone or nephrectomy for advanced RCC
• Migden et al. NEnglJMed 2018 — PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
• Park et al. NEnglJMed 2018 — Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
• Butler et al. NatBiotechnol 2018 — Integrating single-cell transcriptomic data across different conditions, technologies, and species
• Wang et al. NatMed 2018 — Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle
• Hamidi et al. NatRevCancer 2018 — Every step of the way integrins in cancer progression and metastasis
• Lytle et al. NatRevCancer 2018 — Stem cell fate in cancer growth, progression and therapy resistance
• Ferguson et al. NatRevDrugDiscov 2018 — Kinase inhibitors the road ahead
• McMahon et al. NatStructMolBiol 2018 — Yeast surface display platform for rapid discovery of conformationally selective nanobodies
• La et al. Nature 2018 — RNA velocity of single cells
• Sun et al. Nature 2018 — Genomic atlas of the human plasma proteome
• Cohen et al. Science 2018 — Detection and localization of surgically resectable cancers with a multi-analyte blood test
• Pereira et al. Science 2018 — Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice
• Izumchenko et al. AnnOncol 2017 — Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with
• Lee et al. Cell 2017 — Anatomically and functionally distinct lung mesenchymal populations marked by Lgr5 and Lgr6
• Lim et al. Cell 2017 — The principles of engineering immune cells to treat cancer
• Kodack et al. CellRep 2017 — Primary patient-derived cancer cells and their potential for personalized cancer patient care
• Johnson et al. CellRes 2017 — Driving gene-engineered T cell immunotherapy of cancer
• Gupta et al. ClinCancerRes 2017 — Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide-resistant
• Chakravarty et al. JCOPrecisOncol 2017 — OncoKB A precision oncology knowledge base
• Wolchok et al. NEnglJMed 2017 — Overall survival with combined nivolumab and ipilimumab in advanced melanoma
• Zheng et al. NatCommun 2017 — Massively parallel digital transcriptional profiling of single cells
• Batlle et al. NatMed 2017 — Cancer stem cells revisited
• Cramer et al. NatMed 2017 — Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth
• Furman et al. NatMed 2017 — Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and
• Aibar et al. NatMethods 2017 — SCENIC single-cell regulatory network inference and clustering
• Lefrancais et al. Nature 2017 — The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors
• Ott et al. Nature 2017 — An immunogenic personal neoantigen vaccine for patients with melanoma
• Bankhead et al. SciRep 2017 — QuPath open source software for digital pathology image analysis
• Sinha et al. BioProtocol 2016 — Isolation of highly pure primary mouse alveolar epithelial type II cells by flow cytometric cell sorting
• Kebriaei et al. JClinInvest 2016 — Phase I trials using sleeping beauty to generate CD19-specific CAR T cells
• Ruella et al. JClinInvest 2016 — Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
• Turtle et al. JClinInvest 2016 — CD19 CAR-T cells of defined CD4+-CD8+ composition in adult B cell ALL patients
• Rosenberg et al. Lancet 2016 — Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following
• Bray et al. NatBiotechnol 2016 — Near-optimal probabilistic RNA-seq quantification
• Uhlen et al. NatMethods 2016 — A proposal for validation of antibodies
• Broutier et al. NatProtoc 2016 — Culture and establishment of self-renewing human and mouse adult liver and pancreas 3d organoids and their genetic
• OLeary et al. NatRevClinOncol 2016 — Treating cancer with selective CDK46 inhibitors
• Goodwin et al. NatRevGenet 2016 — Coming of age ten years of next-generation sequencing technologies
• Walsh et al. SciRep 2016 — Drug response in organoids generated from frozen primary tumor tissues
• Wang et al. SciRep 2016 — THBS2 is a potential prognostic biomarker in colorectal cancer
• Tirosh et al. Science 2016 — Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
• Ali et al. AnnOncol 2015 — PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating
• Anders et al. Bioinformatics 2015 — HTSeq-a python framework to work with high-throughput sequencing data
• Davenport et al. CancerImmunolRes 2015 — CAR-T cells inflict sequential killing of multiple tumor target cells
• Macosko et al. Cell 2015 — Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets
• Network et al. Cell 2015 — Genomic classification of cutaneous melanoma
• Liberzon et al. CellSyst 2015 — The molecular signatures database (MSigDB) hallmark gene set collection
• Casak et al. ClinCancerRes 2015 — FDA approval summary ramucirumab for gastric cancer
• Lum et al. ClinCancerRes 2015 — Targeted T-cell therapy in stage IV breast cancer A phase I clinical trial
• Chen et al. CurrBiol 2015 — Spliceosomes
• Wang et al. DevCell 2015 — Formin-like 2 promotes beta1-integrin trafficking and invasive motility downstream of PKCalpha
• Kundranda et al. DrugDesDevelTher 2015 — Albumin-bound paclitaxel in solid tumors clinical development and future directions
• Pongor et al. GenomeMed 2015 — A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data
• Ahmed et al. JClinOncol 2015 — Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the
• Awad et al. JClinOncol 2015 — Durable responses with PD-1 inhibition in lung and kidney cancer and the ongoing search for predictive biomarkers
• Cohen et al. JClinOncol 2015 — Controversies in the treatment of local and locally advanced gastric and esophageal cancers
• Hamanishi et al. JClinOncol 2015 — Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
• Maio et al. JClinOncol 2015 — Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine
• Park et al. JClinOncol 2015 — Efficacy and safety of CD19-targeted CAR-T for B-ALL
• Schadendorf et al. JClinOncol 2015 — Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or
• Wang et al. JClinOncol 2015 — Immune therapy in GI malignancies A review
• Ribas et al. LancetOncol 2015 — Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) a randomised,
• Pegram et al. Leukemia 2015 — IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
• Chapman et al. NEnglJMed 2015 — Rapid eradication of a bulky melanoma mass with one dose of immunotherapy
• Motzer et al. NEnglJMed 2015 — Nivolumab versus everolimus in advanced renal-cell carcinoma
• Postow et al. NEnglJMed 2015 — Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
• Robert et al. NEnglJMed 2015 — Nivolumab in previously untreated melanoma without BRAF mutation
• Robert et al. NEnglJMed 2015 — Pembrolizumab versus ipilimumab in advanced melanoma
• Satija et al. NatBiotechnol 2015 — Spatial reconstruction of single-cell gene expression data
• Shukla et al. NatBiotechnol 2015 — Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
• Cristescu et al. NatMed 2015 — Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
• Gao et al. NatMed 2015 — High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
• Long et al. NatMed 2015 — 4-1bb costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
• Newman et al. NatMethods 2015 — Robust enumeration of cell subsets from tissue expression profiles
• Bachireddy et al. NatRevCancer 2015 — Haematological malignancies at the forefront of immunotherapeutic innovation
• Bertotti et al. Nature 2015 — The genomic landscape of response to EGFR blockade in colorectal cancer
• DeLosAngeles et al. Nature 2015 — Hallmarks of pluripotency
• Spranger et al. Nature 2015 — Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity
• Ritchie et al. NucleicAcidsRes 2015 — Limma powers differential expression analyses for RNA-sequencing and microarray studies
• Madore et al. PigmentCellMelanomaRes 2015 — PD-L1 expression in melanoma shows marked heterogeneity within and between patients implications for anti-PD-1pd-L1
• Garrett et al. Science 2015 — Cancer and the microbiota
• Rosenberg et al. Science 2015 — Adoptive cell transfer as personalized immunotherapy for human cancer
• Wu et al. Science 2015 — Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
• Zhang et al. AmJTranslRes 2014 — Comparative membrane proteomic analysis between lung adenocarcinoma and normal tissue by iTRAQ labeling mass
• Nakajima et al. AnnThoracSurg 2014 — Orthotopic lung cancer murine model by nonoperative transbronchial approach
• Bolger et al. Bioinformatics 2014 — Trimmomatic a flexible trimmer for illumina sequence data
• Liao et al. Bioinformatics 2014 — featureCounts an efficient general purpose program for assigning sequence reads to genomic features
• Sun et al. BreastCancerRes 2014 — Construction and evaluation of a novel humanized HER2-specific chimeric receptor
• Doi et al. CancerChemotherPharmacol 2014 — Phase I dose-escalation study of the HSP90 inhibitor AUY922 in japanese patients with advanced solid tumors
• Wang et al. CancerImmunolRes 2014 — Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth
• Gao et al. Cell 2014 — Organoid cultures derived from patients with advanced prostate cancer
• Lee et al. Cell 2014 — Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis
• Heiss et al. ClinCancerRes 2014 — The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites
• Ahmed et al. FEBSLett 2014 — Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
• Love et al. GenomeBiol 2014 — Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
• Watanabe et al. IntJOncol 2014 — A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population
• Barrington et al. JClinOncol 2014 — Role of imaging in the staging and response assessment of lymphoma consensus of the international conference on
• Topalian et al. JClinOncol 2014 — Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
• Yamanaka et al. ModRheumatol 2014 — Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in japan using reimbursement
• Weaver et al. MolBiolCell 2014 — How taxolpaclitaxel kills cancer cells
• Trapnell et al. NatBiotechnol 2014 — The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells
• Zheng et al. NatMed 2014 — Anchored multiplex PCR for targeted next-generation sequencing
• Cancer et al. Nature 2014 — Comprehensive molecular characterization of gastric adenocarcinoma
• Pellegrini et al. Oncologist 2014 — Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma
• Hanzelmann et al. BMCBioinformatics 2013 — GSVA gene set variation analysis for microarray and RNA-seq data
• Dobin et al. Bioinformatics 2013 — STAR ultrafast universal RNA-seq aligner
• Rivera et al. Cell 2013 — Mapping human epigenomes
• Barlan et al. CurrOpinCellBiol 2013 — The journey of the organelle teamwork and regulation in intracellular transport
• Tirino et al. FASEBJ 2013 — Cancer stem cells in solid tumors an overview and new approaches for their isolation and characterization
• Iglesias-Ussel et al. JImmunolMethods 2013 — Isolation of microarray-quality RNA from primary human cells after intracellular immunostaining and
• Hamid et al. NEnglJMed 2013 — Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
• Wolchok et al. NEnglJMed 2013 — Nivolumab plus ipilimumab in advanced melanoma
• Frampton et al. NatBiotechnol 2013 — Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
• Themeli et al. NatBiotechnol 2013 — Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
• Alexandrov et al. Nature 2013 — Signatures of mutational processes in human cancer
• Gao et al. SciSignal 2013 — Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
• Vogelstein et al. Science 2013 — Cancer genome landscapes
• Saunders et al. Bioinformatics 2012 — Strelka accurate somatic small-variant calling from sequenced tumor-normal sample pairs
• Cerami et al. CancerDiscov 2012 — The cBio cancer genomics portal an open platform for exploring multidimensional cancer genomics data
• Glickman et al. Cell 2012 — Converting cancer therapies into cures lessons from infectious diseases
• Nik-Zainal et al. Cell 2012 — Mutational processes molding the genomes of 21 breast cancers
• Weickhardt et al. JThoracOncol 2012 — Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in
• Cheng et al. MolBiolCell 2012 — Myosin 1e coordinates actin assembly and cargo trafficking during clathrin-mediated endocytosis
• Topalian et al. NEnglJMed 2012 — Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
• Langmead et al. NatMethods 2012 — Fast gapped-read alignment with Bowtie 2
• Schindelin et al. NatMethods 2012 — Fiji an open-source platform for biological-image analysis
• Barretina et al. Nature 2012 — The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity
• ENCODE et al. Nature 2012 — An integrated encyclopedia of DNA elements in the human genome
• Network et al. Nature 2012 — Comprehensive molecular characterization of human colon and rectal cancer
• Network et al. Nature 2012 — Comprehensive molecular portraits of human breast tumours
• Bustos et al. ProcNatlAcadSciUSA 2012 — Rab27 and rab3 sequentially regulate human sperm dense-core granule exocytosis
• Scholler et al. SciTranslMed 2012 — Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
• Cahu et al. AnnOncol 2011 — 18f-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature TNK lymphomas a study
• Li et al. BMCBioinformatics 2011 — RSEM accurate transcript quantification from RNA-seq data with or without a reference genome
• Savoldo et al. JClinInvest 2011 — CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
• Robbins et al. JClinOncol 2011 — Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered
• Chen et al. JNatlCancerInst 2011 — Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma phase III randomized trial
• Opitz-Araya et al. JVisExp 2011 — Organotypic hippocampal slice cultures
• Chapman et al. NEnglJMed 2011 — Improved survival with vemurafenib in melanoma with BRAF V600E mutation
• Robert et al. NEnglJMed 2011 — Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
• Robinson et al. NatBiotechnol 2011 — Integrative genomics viewer
• Martin et al. NatRevGenet 2011 — Next-generation transcriptome assembly
• Network et al. Nature 2011 — Integrated genomic analyses of ovarian carcinoma
• Quinlan et al. Bioinformatics 2010 — BEDTools a flexible suite of utilities for comparing genomic features
• Robinson et al. Bioinformatics 2010 — edgeR a bioconductor package for differential expression analysis of digital gene expression data
• Wilkerson et al. Bioinformatics 2010 — ConsensusClusterPlus a class discovery tool with confidence assessments and item tracking
• Jena et al. Blood 2010 — Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
• Madsen et al. DevCell 2010 — Cancer dissemination-lessons from leukocytes
• Morrisey et al. DevCell 2010 — Preparing for the first breath genetic and cellular mechanisms in lung development
• Chen et al. FEBSJ 2010 — Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted
• Weiler-Sagie et al. JNuclMed 2010 — (18)f-FDG avidity in lymphoma readdressed a study of 766 patients
• Hodi et al. NEnglJMed 2010 — Improved survival with ipilimumab in patients with metastatic melanoma
• Wang et al. NucleicAcidsRes 2010 — ANNOVAR functional annotation of genetic variants from high-throughput sequencing data
• Li et al. Bioinformatics 2009 — Fast and accurate short read alignment with burrows-wheeler transform
• Li et al. Bioinformatics 2009 — The sequence AlignmentMap format and SAMtools
• Sugahara et al. CancerCell 2009 — Tissue-penetrating delivery of compounds and nanoparticles into tumors
• DiGiacomo et al. CancerImmunolImmunother 2009 — Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma
• Okamoto et al. CancerRes 2009 — Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of
• Yvon et al. ClinCancerRes 2009 — Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells
• Langmead et al. GenomeBiol 2009 — Ultrafast and memory-efficient alignment of short DNA sequences to the human genome
• Pio et al. JThoracOncol 2009 — Alternative splicing in lung cancer
• JVisExp 2009 — Adenocarcinoma engraftment A method to implant cancer cells into the murine lungs
• DuPage et al. NatProtoc 2009 — Conditional mouse lung cancer models using adenoviral or lentiviral delivery of cre recombinase
• Huang et al. NatProtoc 2009 — Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
• Carpenito et al. ProcNatlAcadSciUSA 2009 — Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137
• Karanikas et al. CancerBiolTher 2008 — Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas implications for
• Arai et al. CurrBiol 2008 — Ypt11 functions in bud-directed transport of the golgi by linking myo2 to the coatomer subunit ret2
• Zhang et al. GenomeBiol 2008 — Model-based analysis of ChIP-Seq (MACS)
• vanMeer et al. NatRevMolCellBiol 2008 — Membrane lipids where they are and how they behave
• Wherry et al. Immunity 2007 — Molecular signature of CD8 T cell exhaustion during chronic viral infection
• Roland et al. MolBiolCell 2007 — Myosin vb interacts with rab8a on a tubular network containing EHD1 and EHD3
• Johannessen et al. CellMolLifeSci 2006 — The multifunctional roles of the four-and-a-half-LIM only protein FHL2
• Lamers et al. JClinOncol 2006 — Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic
• Roeder et al. NatMed 2006 — Dynamic modeling of imatinib-treated chronic myeloid leukemia functional insights and clinical implications
• Lee et al. ProcNatlAcadSciUSA 2006 — Evolution and expression of chimeric POTE-actin genes in the human genome
• Rowinsky et al. SeminOncol 2006 — Novel agents that target tublin and related elements
• Hoepfner et al. Cell 2005 — Modulation of receptor recycling and degradation by the endosomal kinesin KIF16B
• Michor et al. Nature 2005 — Dynamics of chronic myeloid leukaemia
• Subramanian et al. ProcNatlAcadSciUSA 2005 — Gene set enrichment analysis a knowledge-based approach for interpreting genome-wide expression profiles
• Bera et al. Gene 2004 — Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths
• Ferrara et al. NatRevDrugDiscov 2004 — Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
• Ibrahim et al. ClinCancerRes 2002 — Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of
• Dudley et al. Science 2002 — Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
• Jordens et al. CurrBiol 2001 — The rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors
• Fontijn et al. MolCellBiol 2001 — The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis
• Venter et al. Science 2001 — The sequence of the human genome
• Hanahan et al. Cell 2000 — The hallmarks of cancer
• Herrmann et al. CurrOpinCellBiol 2000 — Intermediate filaments and their associates multi-talented structural elements specifying cytoarchitecture and
• Doki et al. BrJCancer 1999 — Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice
• Hirata et al. ClinCancerRes 1999 — Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug
• Chapman et al. JClinOncol 1999 — Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma
• Al et al. JClinOncol 1998 — Sarraf-Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer phase III randomized int…
• Horwich et al. JClinOncol 1997 — Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in
• Cortes et al. JClinOncol 1995 — Docetaxel
• Hwu et al. JExpMed 1993 — Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable
• Jodrell et al. JClinOncol 1992 — Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
• Motzer et al. JClinOncol 1987 — Residual mass an indication for further therapy in patients with advanced seminoma following systemic chemotherapy
• Harding et al. JCellBiol 1983 — Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes